Celiac Disease - Pipeline Review, H2 2015

Published: November 2015
No. of Pages: 83
   

Global Markets Direct’s, ‘Celiac Disease - Pipeline Review, H2 2015’, provides an overview of the Celiac Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Celiac Disease
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Celiac Disease
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Celiac Disease - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Celiac Disease Overview 9
Therapeutics Development 10
Pipeline Products for Celiac Disease - Overview 10
Pipeline Products for Celiac Disease - Comparative Analysis 11
Celiac Disease - Therapeutics under Development by Companies 12
Celiac Disease - Therapeutics under Investigation by Universities/Institutes 13
Celiac Disease - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Celiac Disease - Products under Development by Companies 17
Celiac Disease - Products under Investigation by Universities/Institutes 18
Celiac Disease - Companies Involved in Therapeutics Development 19
Alba Therapeutics Corporation 19
Alvine Pharmaceuticals, Inc. 20
Amgen Inc. 21
Amyra Biotech AG 22
Avaxia Biologics, Inc. 23
Calypso Biotech SA 24
enGene, Inc 25
Glenmark Pharmaceuticals Ltd. 26
ImmusanT, Inc. 27
Intrexon Corporation 28
Provid Pharmaceuticals, Inc. 29
Selecta Biosciences, Inc. 30
Sitari Pharmaceuticals, Inc. 31
Zedira GmbH 32
Celiac Disease - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles AMG-714 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AVX-176 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Biologic to Antagonize HLA-DQ2 for Celiac Disease - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Biologic to Target Gluten and IL-10 for Celiac Disease - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Biologics to Inhibit Transglutaminase 2 for Celiac Disease - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CALY-002 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Enzyme for Celiac Disease - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Enzymes for Celiac Disease - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ERW-1041E - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GBR-830 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
larazotide acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
latiglutenase - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology and Gastrointestinal Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Nexvax-2 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Nexvax-3 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Oligonucleotides for Celiac Disease - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Peptide for Celiac Disease - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Recombinant Protein for Celiac Disease - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Synthetic Peptide to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Vaccine for Celiac Disease - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ZED-101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZED-1098 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ZED-1219 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ZED-1227 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ZED-754 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Celiac Disease - Recent Pipeline Updates 69
Celiac Disease - Dormant Projects 74
Celiac Disease - Product Development Milestones 75
Featured News & Press Releases 75
Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 75
Sep 03, 2015: Glenmark''s Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe 75
Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 76
Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease 76
Nov 19, 2014: ImmusanT’s Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects to Watch 77
Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 78
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 78
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 79
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 80
Apr 19, 2013: ImmusanT’s Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables

Number of Products under Development for Celiac Disease, H2 2015 10
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Comparative Analysis by Unknown Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Celiac Disease - Pipeline by Alba Therapeutics Corporation, H2 2015 19
Celiac Disease - Pipeline by Alvine Pharmaceuticals, Inc., H2 2015 20
Celiac Disease - Pipeline by Amgen Inc., H2 2015 21
Celiac Disease - Pipeline by Amyra Biotech AG, H2 2015 22
Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2015 23
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2015 24
Celiac Disease - Pipeline by enGene, Inc, H2 2015 25
Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015 26
Celiac Disease - Pipeline by ImmusanT, Inc., H2 2015 27
Celiac Disease - Pipeline by Intrexon Corporation, H2 2015 28
Celiac Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2015 29
Celiac Disease - Pipeline by Selecta Biosciences, Inc., H2 2015 30
Celiac Disease - Pipeline by Sitari Pharmaceuticals, Inc., H2 2015 31
Celiac Disease - Pipeline by Zedira GmbH, H2 2015 32
Assessment by Monotherapy Products, H2 2015 33
Number of Products by Stage and Target, H2 2015 35
Number of Products by Stage and Mechanism of Action, H2 2015 37
Number of Products by Stage and Route of Administration, H2 2015 39
Number of Products by Stage and Molecule Type, H2 2015 41
Celiac Disease Therapeutics - Recent Pipeline Updates, H2 2015 69
Celiac Disease - Dormant Projects, H2 2015 74

List of Figures

Number of Products under Development for Celiac Disease, H2 2015 10
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Products, H2 2015 15
Assessment by Monotherapy Products, H2 2015 33
Number of Products by Targets, H2 2015 34
Number of Products by Stage and Targets, H2 2015 34
Number of Products by Mechanism of Actions, H2 2015 36
Number of Products by Stage and Mechanism of Actions, H2 2015 36
Number of Products by Routes of Administration, H2 2015 38
Number of Products by Stage and Routes of Administration, H2 2015 38
Number of Products by Top 10 Molecule Types, H2 2015 40
Number of Products by Stage and Top 10 Molecule Types, H2 2015 40

Published By: Global Markets Direct
Product Code: Global Markets Direct13865


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: